- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05207085
Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults
April 16, 2024 updated by: Yale University
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Titration Study to Assess the Safety, Tolerability, and Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults
This trial aims to evaluate the efficacy, safety and tolerability of valbenazine, titrated to the subject's optimal dose of 40mg or 80mg, administered once daily, for 12 weeks, for the treatment of trichotillomania (TTM) in a double blind placebo controlled design study.
After week 12, subjects will begin a 12-week, open-label portion of the study.
During the open-label portion of the study, all subjects will receive the study drug at their optimal dose.
The primary endpoint of these studies will be the change from baseline of placebo vs. active scores utilizing the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) at the end of Week 12.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Eligible subjects will be randomized in a double-blind manner in a 1:1 ratio to once-daily doses of valbenazine or placebo for 12 weeks.
After week 12, all subjects will begin the 12-week, open-label portion of the study in which they all get their optimal dose.
Follow-up assessments will be conducted at the end of week 26 (2 weeks after the last dose of the study drug).
For subjects randomized to active treatment, the starting dose will be valbenazine 40mg, which may be escalated to 80mg to achieve an optimal dose of valbenazine for each subject.
Dose escalation will occur at the end of week 2 based on the following criteria: 1) the subject's TTM symptoms are not sufficiently controlled per physician investigator assessment and 2) an evaluation by the physician investigator indicates that the subject is tolerating the study drug at the current dose and would likely be able to tolerate the higher dose level.
At week 4, the physician investigator may choose to keep the subject at the higher dose or may reduce to the subject's prior tolerated dose (in subjects who have had dose escalation).
If a subject's optimal dose was established as 40mg at week 2, no dose escalation will be allowed at week 4.
At any time after week 2, the physician investigator may decrease the dose to the previous dose for any subject who had a dose escalation and who is unable to tolerate a given dose increase.
The investigator may reduce the subject's dose only one time.
Subjects who are unable to tolerate the starting dose or resumption of the 40mg dose will be discontinued from the study.
The subject will continue at the dose reached during the optimization period for the remainder of the 12-week treatment period.
To maintain the study blind, subjects randomized to placebo in each weight group will be subjected to the same dose escalation requirements, but will receive only placebo during the treatment period.
Following the 12-week, double-blind study, all subjects will be offered the option to receive open-label valbenazine for 12 weeks.
In order to protect the blind in the first phase of the trial all subjects will receive 40mg of valbenazine from week 12 to week 14 and then be titrated on the study medication similar to the first phase of the trial from that point forward.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Angeli Landeros, MD
- Phone Number: 203737-4539
- Email: blochresearch@yale.edu
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale Child Study Center
-
Contact:
- Angeli Landeros, MD
- Phone Number: 203-737-4539
- Email: angeli.landeros@yale.edu
-
Contact:
- Michael Bloch, MD
- Phone Number: (203)785-6906
- Email: michael.bloch@yale.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have documentation of written and witnessed consent from the subject
- Male or female adult between the ages of 18-65, inclusive
- Be in good health as determined by medical history, physical examination, laboratory assessments and 12-lead ECG
- On stable psychiatric medication regime of 4 weeks prior to beginning the trial and not anticipating changes during the trial
- Subjects of child-bearing potential must agree to use contraception (condoms for men, birth control pill or diaphragm for women) consistently from screening until 30 days (female) or 90 days (male) after the last dose of the study drug. A female subject of childbearing potential is defined as a female capable of becoming pregnant, which includes subjects who have had their first menstrual cycle (i.e., menarche) and are not surgically sterile (i.e., bilateral oophorectomy, hysterectomy or bilateral tubal ligation for at least 3 months prior to screening) or have not experienced menopause and subsequently are no longer of childbearing potential. A male subject of childbearing potential is defined as a subject who has reached spermarche and has not been vasectomized for at least 3 months prior to screening. Subjects who practice total abstinence from sexual intercourse as the preferred lifestyle are not required to use contraception (periodic abstinence is not acceptable).
- Female subjects must have a negative urine pregnancy test at Day 1 (baseline).
- Negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates or cannabinoids) at screening and baseline. Subjects on stable doses of prescribed and supervised (not as needed) benzodiazepines, opiates or psychostimulants (participants with ADHD) can participate in the study.
- Subjects must have a negative alcohol breath test at screening and at Day 1 (baseline).
- Be willing to adhere to the study regime and study procedures described in the protocol and informed consent forms, including all requirements at the study center and return for the follow-up visit
- Have symptoms that cause marked distress or significant impairment in occupational and/or social function
- Have a stable psychiatric status (TTM) as clinically determined by the investigator.
- Meet DSM-5 criteria for TTM
- Significant current TTM symptoms: 17 or greater score on NIMH-TSS/TIS
Exclusion Criteria:
- Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental disorder or intellectual disability (IQ<70)
- Recent changes in medications (less than 4 weeks) in other medications that have potential effects on TTM severity. Medication change is defined to include dose changes or medication discontinuation.
- Currently taking antipsychotic medications or other medications that affect the dopamine system (e.g. psychostimulant medications).
- Recent changes in behavior treatment (less than 4 weeks) or initiation of therapy (within 12 weeks) for TTM/Obsessive Compulsive Disorder (OCD)
- Taking co-medications (over the counter or prescription) that may have a drug interaction with valbenazine as described in the United States Prescribing Information for INGREZZA. Patients who are taking co-medications with the potential to cause QT prolongations will not be excluded unless their ECG shows QT prolongation already present.
- Positive pregnancy test or drug screening test
- Currently pregnant or lactating
- Significant medical comorbidity
- Excessive use of tobacco and/or nicotine-containing products (based on the investigator's assessment or more than 1½ pack of cigarettes per day, 1 can of chewing/dipping tobacco per day, 54mg of nicotine-containing smoking cessation products per day, or any nicotine products or combination of products that exceed 54mg per day) within 30 days of screening
- History of substance (drug or alcohol) dependence or abuse within 3 months before Baseline, as defined by DSM-5 criteria for Substance Use Disorder
- Known history of neuroleptic malignant syndrome
- Known history of long QT syndrome or cardiac arrhythmia
- Have a screening or Day 1 average triplicate ECG corrected QT interval using Fridericia's formula(33) (QTcF) of >450msec or the presence of any clinically significant cardiac abnormality
- Have a blood loss ≥250 mL or donated blood within 56 days or donated plasma within 7 days of Day 1 (baseline).
- Have a significant risk of suicidal or violent behavior based on prior medical history and clinical judgement.
- Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors (e.g., tetrabenazine).
- Have a history of or suspected poor compliance in clinical research studies.
- Have previous experience with valbenazine or previously participated in a valbenazine clinical study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Valbenazine
Participants randomized1:1 to receive valbenazine
|
Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
Other Names:
|
Placebo Comparator: Placebo
Participants randomized 1:1 to receive placebo
|
Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Massachusetts General Hospital Hairpulling Scale (MGH-HPS) from baseline to Week 12
Time Frame: baseline to week12
|
Massachusetts General Hospital Hairpulling Scale (MGH-HPS) scores range from 0-28 with 28 being the most severe.
The lower the total score, the lower the severity level.
This scale is given and measured once every 2 weeks for a total of 12 weeks.
|
baseline to week12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Improvement Scale - Trichotillomania Severity (CGI-TTM) score at endpoint
Time Frame: Week 12
|
Each of the Clinical Global Improvement Scale -Trichotillomania (CGI-TTM) response categories was assigned a numerical score as follows: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = Not changed; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse.
Responder status on Clinical Global Improvement Scale as having a CGI-TTM score at endpoint less than or equal to 2.
|
Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael H. Bloch, MD, Yale University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Grant JE, Chamberlain SR. Trichotillomania. Am J Psychiatry. 2016 Sep 1;173(9):868-74. doi: 10.1176/appi.ajp.2016.15111432.
- Bloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, Pittenger C, Leckman JF, Coric V. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry. 2007 Oct 15;62(8):839-46. doi: 10.1016/j.biopsych.2007.05.019. Epub 2007 Aug 28.
- United States Prescribing Information for INGREZZA. San Diego, CA 92130: Neurocrine Biosciences, Inc.; 2020.
- McGuire JF, Ung D, Selles RR, Rahman O, Lewin AB, Murphy TK, Storch EA. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. J Psychiatr Res. 2014 Nov;58:76-83. doi: 10.1016/j.jpsychires.2014.07.015. Epub 2014 Jul 26.
- Franklin ME, Zagrabbe K, Benavides KL. Trichotillomania and its treatment: a review and recommendations. Expert Rev Neurother. 2011 Aug;11(8):1165-74. doi: 10.1586/ern.11.93.
- Sarva H, Henchcliffe C. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Expert Rev Clin Pharmacol. 2018 Mar;11(3):209-217. doi: 10.1080/17512433.2018.1429264. Epub 2018 Jan 23.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2023
Primary Completion (Estimated)
October 15, 2025
Study Completion (Estimated)
October 15, 2026
Study Registration Dates
First Submitted
December 21, 2021
First Submitted That Met QC Criteria
January 11, 2022
First Posted (Actual)
January 26, 2022
Study Record Updates
Last Update Posted (Actual)
April 18, 2024
Last Update Submitted That Met QC Criteria
April 16, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000026788
- No NIH funding (Other Identifier: 10.11.23)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trichotillomania (Hair-Pulling Disorder)
-
Johns Hopkins UniversityRecruitingTrichotillomania | Trichotillomania (Hair-Pulling Disorder) | Hair PullingUnited States
-
University of ChicagoNot yet recruitingTrichotillomania (Hair-Pulling Disorder) | DermatillomaniaUnited States
-
University of ChicagoCompletedTrichotillomania (Hair-Pulling Disorder) | DermatillomaniaUnited States
-
University of ChicagoRecruitingTrichotillomania (Hair-Pulling Disorder) | Skin-PickingUnited States
-
American UniversityCompletedTrichotillomania (Hair-Pulling Disorder) | Skin-PickingUnited States
-
American UniversityTrichotillomania Learning CenterCompletedTrichotillomania | Hair-Pulling DisorderUnited States
-
University of ChicagoCompletedTrichotillomania | Hair Pulling DisorderUnited States
-
Yale UniversityTrichotillomania Learning CenterCompleted
-
University of ChicagoCompleted
-
University of ChicagoRecruitingObsessive-Compulsive Disorder | Tourette Syndrome | Trichotillomania (Hair-Pulling Disorder) | Hoarding DisorderUnited States
Clinical Trials on Valbenazine Oral Capsule
-
Neurocrine BiosciencesCompletedTardive Dyskinesia (TD)United States, Puerto Rico
-
Neurocrine BiosciencesCompletedTourette SyndromeUnited States, Puerto Rico
-
Neurocrine BiosciencesTerminatedTourette SyndromeUnited States, Puerto Rico
-
Neurocrine BiosciencesCompletedTardive Dyskinesia (TD)United States, Puerto Rico
-
Stephen RuedrichNeurocrine BiosciencesNot yet recruitingIntellectual Disability | Developmental Disabilities | Tardive DyskinesiaUnited States
-
Neurocrine BiosciencesTerminatedTourette SyndromeUnited States, Puerto Rico
-
Neurocrine BiosciencesCompletedTardive DyskinesiaUnited States
-
Brigham and Women's HospitalCompleted
-
Aelis FarmaNational Institute on Drug Abuse (NIDA)CompletedHealthy VolunteersUnited States
-
Brigham and Women's HospitalEnrolling by invitation